{"nctId":"NCT00764738","briefTitle":"Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration","startDateStruct":{"date":"2008-10"},"conditions":["Neovascular Age Related Macular Degeneration"],"count":91,"armGroups":[{"label":"Monthly","type":"ACTIVE_COMPARATOR","interventionNames":["Device: OCT, Multifocal ERG, Microperimetry","Drug: Ranibizumab Ophthalmic"]},{"label":"As Needed","type":"ACTIVE_COMPARATOR","interventionNames":["Device: OCT, Multifocal ERG, Microperimetry","Drug: Ranibizumab Ophthalmic"]}],"interventions":[{"name":"OCT, Multifocal ERG, Microperimetry","otherNames":[]},{"name":"Ranibizumab Ophthalmic","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability to provide written informed consent and comply with study assessments for the full duration of the study.\n* Age greater or equal to 50 years old.\n* Patients with active neovascular AMD\n\nExclusion Criteria:\n\n* Pregnancy (Positive pregnancy test) or lactation.\n* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.\n* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated\n* Participation in another simultaneous medical investigation or trial\n* Concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma)\n* Previous PDT therapy\n* Previous intravitreal steroid therapy within last 3 months\n* Previous anti-VEGF therapy in the past month","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Multifocal Electroretinography N1-P1 Amplitude","description":"As measured within the central ring of the multifocal electroretinography study this measurement is the difference between the first positive peak (P1) and the first negative peak (N1).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"0.4"},{"groupId":"OG001","value":"5.3","spread":"0.4"},{"groupId":"OG002","value":"4.9","spread":"0.4"},{"groupId":"OG003","value":"4.0","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.4"},{"groupId":"OG001","value":"4.7","spread":"0.4"},{"groupId":"OG002","value":"4.4","spread":"0.4"},{"groupId":"OG003","value":"3.6","spread":"0.4"}]}]}]},{"type":"PRIMARY","title":"Microperimetry Mean Sensitivity","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"0.8"},{"groupId":"OG001","value":"5.1","spread":"0.7"},{"groupId":"OG002","value":"5.7","spread":"0.7"},{"groupId":"OG003","value":"4.6","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.7"},{"groupId":"OG001","value":"7.3","spread":"0.8"},{"groupId":"OG002","value":"7.3","spread":"0.7"},{"groupId":"OG003","value":"6.6","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Best Corrected Visual Acuity","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":"4.0"},{"groupId":"OG001","value":"52.6","spread":"3.3"},{"groupId":"OG002","value":"48.6","spread":"3.5"},{"groupId":"OG003","value":"54.5","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":"3.8"},{"groupId":"OG001","value":"58.6","spread":"3.4"},{"groupId":"OG002","value":"55.4","spread":"3.4"},{"groupId":"OG003","value":"61.1","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Central Foveal Thickness on Optical Coherence Tomography","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"341.2","spread":"21.9"},{"groupId":"OG001","value":"298.1","spread":"16.8"},{"groupId":"OG002","value":"308.2","spread":"14.9"},{"groupId":"OG003","value":"331.1","spread":"26.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"246.8","spread":"17.0"},{"groupId":"OG001","value":"227.9","spread":"12.2"},{"groupId":"OG002","value":"231.7","spread":"14.3"},{"groupId":"OG003","value":"242.7","spread":"13.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Injection Site Irritation","Corneal Abrasion"]}}}